文献速递白血病

OPTIC试验5年随访:帕纳替尼基于疗效调整剂量在慢性期CML的长期结局

Five-year follow-up of OPTIC: long-term efficacy, safety, and mutation analyses of ponatinib in chronic-phase chronic myeloid leukemia from a randomized phase 2 trial.
PubMed 文献 · Leukemia · 2026-07-24

OPTIC是一项随机2期试验,283例酪氨酸激酶抑制剂耐药或T315I阳性的慢性期CML患者随机接受帕纳替尼45mg、30mg或15mg每日一次起始剂量,45mg和30mg组在获得≤1% BCR::ABL1IS后减至15mg。5年随访显示,45mg组≤1% BCR::ABL1IS率最高(60%),T315I阳性患者中45mg组无进展生存和总生存也最优,支持基于疗效的剂量策略。

要点

  • 45mg起始并应答后减量组5年BCR::ABL1IS≤1%率达60%,高于30mg和15mg组。
  • T315I阳性患者中45mg组5年BCR::ABL1IS≤1%、PFS和OS均最高。
  • 暴露调整的动脉闭塞事件率45mg组4.1例/100患者年,30mg组3.8,15mg组2.0。

核心结论

  • 基于疗效的帕纳替尼剂量策略在三线慢性期CML中显示长期临床获益,尤其对T315I突变患者。

研究设计与样本

  • 随机2期OPTIC试验(NCT02467270),283例患者随机分入45mg、30mg、15mg每日一次起始剂量组(n=94、95、94),45mg和30mg组获得≤1% BCR::ABL1IS后减至15mg。

主要发现

  • 中位随访75-78个月,5年时45mg、30mg、15mg组分别有60%、41%、40%患者达到≤1% BCR::ABL1IS。
  • 5年无进展生存率分别为63%、57%、60%,总生存率均超过80%。
  • T315I突变患者中,45mg组5年≤1% BCR::ABL1IS率、PFS和OS最高。
  • 暴露调整的动脉闭塞事件率分别为4.1、3.8、2.0例/100患者年,T315I阳性患者中结果相当。

关键数值与推荐

  • 45mg起始组5年≤1% BCR::ABL1IS率为60%,30mg组41%,15mg组40%。
  • 5年PFS率45mg组63%,30mg组57%,15mg组60%;OS率均超过80%。
  • 动脉闭塞事件暴露调整率45mg组4.1例/100患者年,30mg组3.8,15mg组2.0。

临床怎么用

  • 对TKI耐药或不耐受的慢性期CML,可考虑帕纳替尼45mg起始,获得≤1% BCR::ABL1IS后减至15mg以平衡疗效与毒性。
  • T315I突变患者可能从45mg起始并应答后减量的策略中获益更多。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The primary analysis of the phase 2 OPTIC trial (NCT02467270) demonstrated optimal benefit:risk with response-based ponatinib dosing (45 mg once daily (QD) reduced to 15 mg QD) upon achieving ≤1% BCR::ABL1IS in patients with tyrosine kinase inhibitor-resistant or T315I-positive chronic-phase chronic myeloid leukemia (CP-CML). Here, we report 5-year long-term outcomes. Overall, 283 patients were randomized to 45-mg, 30-mg, or 15-mg QD starting doses (n = 94, 95, and 94, respectively), with dose reduction to 15 mg QD upon response in the 45-mg and 30-mg cohorts. At data cutoff, 61 patients remained on trial. Median follow-up time was 75-78 months. By 5 years, 60%, 41%, and 40% of patients in the 45-mg, 30-mg, and 15-mg cohorts, respectively, achieved ≤1% BCR::ABL1IS. Five-year progression-free survival rates were 63%, 57%, and 60%, respectively, by cohort; overall survival rates exceeded 80%. In patients with a T315I mutation, 5-year rates of ≤1% BCR::ABL1IS, PFS, and OS were highest in the 45-mg cohort. Exposure-adjusted rates of adjudicated arterial occlusive events were 4.1, 3.8, and 2.0 patients per 100 patient-years, respectively, by cohort; results were comparable in T315I-positive patients. These findings support long-term clinical benefit of response-based ponatinib dosing in third-line CP-CML, especially in patients with the T315I mutation.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Kantarjian H, Deininger M, Apperley JF, et al. Five-year follow-up of OPTIC: long-term efficacy, safety, and mutation analyses of ponatinib in chronic-phase chronic myeloid leukemia from a randomized phase 2 trial. Leukemia. 2026. PMID: 42498834. doi:10.1038/s41375-026-03009-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。